Trump order promises to bring pharma manufacturing back to USA

US President Donald Trump has signed an executive order attempting to restore a robust domestic manufacturing base for prescription drugs in the USA.

The order directs the US Food and Drug Administration (FDA) to reduce the amount of time it takes to approve domestic pharmaceutical manufacturing plants by eliminating duplicative and unnecessary requirements, streamlining reviews and working with domestic manufacturers to provide early support before facilities come online.

To hinder competition from overseas, the order directs the FDA to increase fees for and inspections of foreign manufacturing plants and to improve enforcement of active pharmaceutical ingredient source reporting by foreign drug producers, and consider publicly displaying a list of facilities that do not comply.